NASDAQ:VVOS | Free Cash Flow | Vivos Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$6.01M$18,000.00-$6.03M
2025-12-31-$3.81M$1.53M-$5.34M
2025-03-31-$3.8M$122,000.00-$3.92M
2024-12-31-$2.94M$165,000.00-$3.11M
2024-03-31-$2.52M$151,000.00-$2.67M
2023-12-31-$2.75M$165,000.00-$2.91M
2023-03-31-$3.54M$239,000.00-$3.78M
2022-12-31-$3M$200,000.00-$3.2M
2022-03-31-$6.08M$120,000.00-$6.2M
2021-12-31-$4.12M$382,000.00-$4.5M
2021-03-31-$3.86M$262,000.00-$4.12M
2020-12-31-$3.62M$94,989.00-$3.71M
2020-03-31-$436,910.00$5,204.00-$442,114.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$15.26M$2.34M-$17.6M
2024-12-31-$12.69M$568,000.00-$13.26M
2023-12-31-$11.95M$803,000.00-$12.75M
2022-12-31-$19.59M$924,000.00-$20.51M
2021-12-31-$15.74M$2.4M-$18.13M
2020-12-31-$5.68M$120,000.00-$5.8M
2019-12-31-$5.34M$175,599.00-$5.52M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.